Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the Americ...
04 November 2016 - 12:01AM
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
today announced that two abstracts have been accepted for poster
presentation at the 58th Annual Meeting of the American
Society of Hematology (ASH) in San Diego, CA, December 3 - 6,
2016.
“The data to be presented at ASH expand
Achillion's understanding of complement biology and demonstrate the
potential advantages of inhibition of factor D in treatment of
complement-mediated diseases,” said David Apelian, M.D., Ph.D. and
Chief Medical Officer of Achillion Pharmaceuticals. “This and other
research recently presented by Achillion scientists highlight the
potential of our approach as we continue to advance ACH-4471, our
first small-molecule factor D inhibitor, through clinical
development.”
Upcoming Poster
Presentations
The poster titled ‘Evaluation of
bacteria-mediated potential “Bystander” hemolysis of PNH red cells
in vitro: No evidence of significant complement classical or lectin
pathway-mediated hemolysis induced by microorganisms.’
will be presented by Dr. Xuan Yuan from the laboratory of Dr.
Robert Brodsky, Johns Hopkins University, a leading PNH expert.
Other authors on the poster include: Guangwei Yang; Jane A.
Thanassi; Manuel D. Galvan; Steven D. Podos and Mingjun Huang of
Achillion, as well as Dr. Brodsky.
This research demonstrated that PNH red cells
were not subjected to theoretical “bystander hemolysis” when
incubated with the bacteria tested, suggesting no increased risk of
pathogen-induced hemolytic breakthrough in PNH patients if treated
with a complement alternative pathway (AP) inhibitor.
A second poster titled ‘Effect of
complement inhibition by anti-C5 (eculizumab) or a small molecule
inhibitor of Factor D (ACH-4471) on survival of meningococci in
blood from vaccinated adults’ will be presented by Dr. Dan
M. Granoff, UCSF Benioff Children’s Hospital, a world expert on
meningococcal infections. Other authors are Monica Konar and
Eduardo Lujan of UCSF Benioff Children’s Hospital.
Data from this research suggests that
vaccination may be more effective in decreasing the risk of
meningococcal disease in the presence of an AP inhibitor as
compared to a C5 inhibitor.
All of the 2016 ASH Annual Meeting abstracts can
be accessed here:http://www.hematology.org/Annual-Meeting/
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is
a science-driven, patient-focused company seeking to leverage its
strengths across the continuum from discovery to commercialization
in its goal of providing better treatments for people with serious
diseases. The company employs a highly-disciplined discovery and
development approach that has allowed it to pursue best-in-class
oral antiviral therapy for chronic hepatitis C (HCV) and build a
platform of potent and specific complement inhibitors. Achillion is
rapidly advancing its efforts to become a fully-integrated
pharmaceutical company with a goal of bringing life-saving
medicines to patients with rare diseases. More information is
available at http://www.achillion.com
Cautionary Note Regarding
Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks, uncertainties and
other important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements.
Achillion may use words such as “expect,” “anticipate,” “project,”
“intend,” “plan,” “aim,” “believe,” “seek,” “ estimate,” “can,”
“focus,” “will,” “look forward,” “goal,” and “may” and similar
expressions to identify such forward-looking statements. These
forward-looking statements also include statements about: the
Company’s expected plans, timing, data readouts and results from
ongoing and planned clinical trials of both ACH-4471 and HCV
development candidates being advanced by Janssen under the
Company’s collaboration with Janssen; and statements concerning the
Company’s strategic goals, milestone plans, and prospects. Among
the important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are risks relating to, among other things Achillion’s ability to:
advance the preclinical and clinical development of its complement
factor D inhibitors under the timelines it projects in current and
future preclinical studies and clinical trials; obtain and maintain
patent protection for its drug candidates and the freedom to
operate under third party intellectual property; demonstrate in any
current and future clinical trials the requisite safety, efficacy
and combinability of its drug candidates; obtain and maintain
necessary regulatory approvals; establish commercial manufacturing
arrangements; identify, enter into and maintain collaboration
agreements with third-parties, including the current collaboration
with Janssen; compete successfully in the markets in which it seeks
to develop and commercialize its product candidates and future
products; manage expenses; manage litigation; raise the substantial
additional capital needed to achieve its business objectives; and
successfully execute on its business strategies. Furthermore,
because Janssen is solely responsible for the development and
commercialization of our HCV assets under the exclusive worldwide
license we granted to it and has the deciding vote on all
collaboration matters, Janssen generally has full discretion over
all development plans and strategies and may not advance the HCV
programs in the time frames Achillion or Janssen projects, or at
all, including with regard to the current and planned phase 2a and
phase 2b combination trials that include our licensed drug
candidates. These and other risks are described in the reports
filed by Achillion with the U.S. Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
fiscal quarter ended June 30, 2016, and its subsequent SEC
filings.
In addition, any forward-looking statement in
this press release represents Achillion’s views only as of the date
of this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Investors:
Glenn Schulman, PharmD, MPH
Executive Director, Investor Relations
Achillion Pharmaceuticals, Inc.
Tel. (203) 752-5510
gschulman@achillion.com
Media:
Liz Power
Senior Director, Public Relations
Achillion Pharmaceuticals, Inc.
Tel: (203) 752-5509
lpower@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2024 to May 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From May 2023 to May 2024